Are there any pharmacokinetic or clinical interactions among zonisamide, levetiracetam (Keppra), and low‑dose naltrexone in an adult without significant hepatic or renal disease?

No Clinically Significant Pharmacokinetic Interactions Expected

The combination of zonisamide, levetiracetam (Keppra), and low-dose naltrexone can be used together without major pharmacokinetic concerns in adults with normal hepatic and renal function, though monitoring for additive central nervous system effects and specific adverse events is warranted.

Pharmacokinetic Profile of Each Agent

Levetiracetam (Keppra)

• Minimal interaction potential: Levetiracetam is not metabolized by cytochrome P450 enzymes and does not induce or inhibit these pathways 111
• Less than 10% protein-bound, eliminating competition for binding sites 1
• Primarily renally excreted (66% unchanged) with minor non-P450 enzymatic hydrolysis 1
• Studies confirm levetiracetam does not affect plasma concentrations of carbamazepine, valproic acid, topiramate, or lamotrigine 1
• Levetiracetam appears devoid of significant enzyme inducing or inhibiting properties 2

Zonisamide

• Extensively metabolized but does not significantly induce or inhibit major drug-metabolizing enzymes at therapeutic doses 2
• May have carbonic anhydrase inhibitor effects, creating risk for metabolic acidosis and nephrolithiasis 3
• No documented interactions with levetiracetam in the literature

Low-Dose Naltrexone

• When used at low doses (typically 1.5-4.5 mg, far below the 50 mg FDA-approved dose for alcohol use disorder), naltrexone has minimal systemic effects
• Standard-dose naltrexone (50 mg) is primarily hepatically metabolized but does not appear to significantly affect cytochrome P450 pathways at clinically relevant concentrations
• The opioid antagonist mechanism does not interact with antiepileptic drug mechanisms

Key Clinical Considerations

Monitor for Additive CNS Effects

While pharmacokinetic interactions are minimal, pharmacodynamic interactions warrant attention:

• All three agents can cause CNS effects (sedation, dizziness, cognitive slowing)
• Zonisamide and levetiracetam may both contribute to behavioral changes or mood disturbances
• Start with conservative dosing and titrate gradually

Specific Monitoring Parameters

For Zonisamide:

• Serum bicarbonate levels (risk of metabolic acidosis) 3
• Adequate hydration to prevent nephrolithiasis
• Avoid in patients with sulfonamide allergy

For Levetiracetam:

• Behavioral changes, particularly irritability or depression
• Renal function if impaired (requires dose adjustment) 1

For Low-Dose Naltrexone:

• Hepatic function at baseline, though hepatotoxicity risk is primarily with standard doses 4
• Ensure patient is not on chronic opioid therapy (absolute contraindication) 56

Important Contraindications

Naltrexone must not be used with:

• Chronic opioid medications (will precipitate withdrawal and block opioid analgesia) 56
• Acute opioid use within 7-10 days

Use caution with naltrexone in:

• Patients with seizure disorders when combined with bupropion (not applicable here as low-dose naltrexone monotherapy) 56
• Severe hepatic impairment, though low-dose naltrexone carries less risk than standard dosing 4

Practical Prescribing Approach

1. Verify no opioid use before initiating naltrexone
2. Obtain baseline labs: comprehensive metabolic panel (for bicarbonate, electrolytes, renal/hepatic function)
3. Start conservatively: Use established dosing for each agent individually, avoiding aggressive titration of multiple agents simultaneously
4. Monitor at 2-4 weeks: Assess for CNS side effects, check serum bicarbonate if on zonisamide
5. Recheck labs at 3 months: Metabolic panel to assess for zonisamide-related acidosis or electrolyte disturbances

Dose Adjustments Not Required

• No dose adjustments needed for any agent based solely on co-administration with the others
• Standard dosing guidelines for each medication apply
• Adjust levetiracetam only if renal impairment develops 1

Bottom Line

This is a pharmacokinetically safe combination with no expected alterations in drug levels or clearance. The primary clinical concern is additive CNS depression and monitoring for zonisamide-specific metabolic complications (acidosis, kidney stones). Ensure absolute avoidance of opioids when using naltrexone, even at low doses.